Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Oatly Group AB - ADR — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Oatly Group AB - ADR trades at $9.85 (market cap $307.57M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 129.7× Oatly Group AB - ADR's market cap. Which is the better fit depends on your goals.
| ALNY | OTLY | |
|---|---|---|
Market Cap | $39.89B | $307.57M |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $18.54 |
52-Week Low | $278.09 | $8.03 |
Enterprise Value | $38.15B | $805.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
OTLY trades at $9.85, up 2.82% today, with a bullish technical signal from ADX indicators. Revenue growth is steady, reaching $862M in 2025, but profitability remains elusive with a net income margin of -17.06%. The company continues to burn cash, though the rate has improved from previous years. Recent news includes new product launches in Canada and an upcoming Q2 2026 earnings report on July 22, 2026.
The outlook is mixed: strong brand presence and revenue growth offer potential, but persistent losses, high debt, and negative cash flow pose significant risks. Analyst sentiment is divided, with 44% recommending buy and 50% hold. Investment hinges on OTLY's ability to achieve profitability and manage its cash runway effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
